Ergomotion Announces Opening of First Manufacturing Facility in North America
30.10.2020 00:28:00 EET | Business Wire | Press release
Ergomotion, part of the Keeson Technology Group and the largest manufacturer of adjustable bases worldwide, will open a 250,000 square foot manufacturing facility in Ciudad Juárez, Chihuahua, the company’s first assembly plant in North America. The expansion was fueled by the decision to increase product capabilities, oversee manufacturing functions, and ultimately to stay closer to Ergomotion’s customer base in the United States.
“We see a prime opportunity with the North America expansion to enhance the customer service experience in the U.S.,” says Johnny Griggs, Chief Operating Officer at Ergomotion. “Our goal is to provide our partners with world class manufacturing and supply chain and to help grow and strengthen their business. We’re excited to partner with Ciudad Juárez to expand our manufacturing capabilities and make this project viable and successful.”
Ergomotion is making a significant investment that will allow for the creation of 400 jobs, within the local economy. The Juárez facility is located in the high growth southeast quadrant of the city and is approximately 8.5 miles from the U.S. border. The project expects to direct capital investment of $4.5 million USD. Ergomotion’s long-term goal is to strengthen their operations and continue to open new facilities in the United States to better serve existing customers, retailers and strategic partners.
“Ciudad Juárez is thrilled to see Ergomotion grow their North American footprint here, in our hometown,” says Hector Armando Cabada Alvidrez, Mayor of Ciudad Juárez. “We are looking forward to working together to strengthen our local economy and seeing the opportunities that the expansion will create for our community.”
“Our state is proven to be one of the most competitive in the world for manufacturing. We are confident that no effort will be spared to continue making our region the most innovative, efficient and fast growing in North America. We know Ergomotion will be pleased with the workforce in Ciudad Juárez and hope this will be their new home for many decades to come,” says Alejandra de la Vega, Secretary of Innovation and Economic Development of the State of Chihuahua.
The new manufacturing facility will accommodate the constant growth surge that the adjustable base category has experienced over the past 10 years and during the pandemic. The facility will include manual and semi-automatic operations that will support continued enhancement of customer service within the U.S., ensuring a reliable and high-quality supply chain for Ergomotion products.
ABOUT ERGOMOTION
Ergomotion, headquartered in Santa Barbara, California, is the largest manufacturer of adjustable bases worldwide. The company’s products are created to provide a holistic wellness solution infused with smart technology to enrich sleep, health, and the overall quality of life. Ergomotion’s adjustable bases are designed to accommodate the industry’s leading mattresses and to seamlessly integrate with existing bed frames. The products have been sold in more than 30 countries to over 170 major brands. Ergomotion is part of the Keeson Technology Group family based in Jiaxing City, China. To learn more about Ergomotion visit www.ergomotion.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029006319/en/
Contact information
Cynthia Murga
Cynthia.Murga@9thWonder.com
Direct: 713-935-5766
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom